II. Indications
- HIV Infection (combination therapy)
-
Chronic Hepatitis B Infection (compensated liver disease)
- HIghly potent against HBV and among preferred agents
- Maintains activity in HBV despite Lamivudine resistance
III. Preparations
- Tenofovir disoproxil Fumarate (TDF, Viread)
- Covered on this page
- Original Tenofovir formulation and used in Stribild, Truvada and Complera
- Associated with nephrotoxicity and decreased Bone Mineral Density
- Preparations
- Tablets: 150, 200, 250 and 300 mg
- Oral powder for solution: 40 mg per 1 gram scoop
- Mix with 2 to 4 ounces of non-liquid soft food (e.g. applesauce, pureed food, yogurt)
-
Tenofovir Alafenamide Fumarate (TAF, Vemlidy)
- See Tenofovir Alafenamide
- Tenofovir formulation released in 2016 and used in Genvoya, Descovy, Odefsey
- TAF appears to have less adverse Renal Function and Bone Mineral Density effects than the original TDF
- TAF is associated with greater weight gain and dyslipidemia than TDF
IV. Mechanism
- Nucleoside Reverse Transcriptase Inhibitor (nRTI)
- Prodrug hydrolyzed in vivo to Tenofovir
- Tenofovir is a Nucleotide analog of Adenosine 5-Monophosphate
V. Precautions
- Risk of severe HBV exacerbation on discontinuation
- Monitor for at least 2 months after discontinuation
- Risk of induced HIV resistance in undiagnosed HIV coinfection
- HIV Test before use
- Do NOT use in monotherapy in HBV/HIV infected patients
VI. Dosing
-
General
- Must be used in combination with other agents when treating HIV Infection (e.g. with Lamivudine or Emtricitibine)
- Adult
- Tenofovir Disoproxil 300 mg orally daily
- Child (age >= 2 years, weight >=10 kg)
- Tenofovir Disoproxil 8 mg/kg once daily
-
Renal Dosing (Adults)
- Consider alternative agents if eGFR <60 ml/min AND Drug Interactions that raise TDF levels (see below)
- eGFR 30 to 49 ml/min: Tenofovir Disoproxil 300 mg every 48 hours
- eGFR 10 to 29 ml/min: Tenofovir Disoproxil 300 mg twice weekly
- Hemodialysis: 300 mg once weekly after Hemodialysis
VII. Adverse Effects
- See nRTI for adverse effects attributed to the class
- Renal dysfunction
- Increased Serum Creatinine
- Proteinuria
- Electrolyte abnormalities
- Nephrotoxicity with Acute Renal Failure (1% risk)
- Associated with longer duration of therapy, advanced HIV or pre-existing renal disease
- Fanconi Syndrome like-reaction
- Avoid with Nephrotoxic Drugs
- Gastrointestinal
- Miscellaneous
- Headache
- Hepatitis B flares on withdrawal of medication
- Fatigue
- Rash
- Decrease Bone Mineral Density
IX. Drug Interactions
- Avoid Tenofovir Disoproxil in combination with the following
- Adefovir
- Didanosine
- Unboosted Atazanavir
- Agents that raise Tenofovir Disoproxil levels (monitor for toxicity including Renal Function)
- Ledipasvir
- Velpatasvir
- Ritonavir
- Cobicistat
X. Monitoring
- Obtain baseline Renal Function, Phosphorus and Urine Protein, then at 2-8 weeks, and then every 3-6 months
XI. Resources
- Tenofovir Disoproxil (DailyMed)
XII. References
Images: Related links to external sites (from Bing)
Related Studies
tenofovir disoproxil (on 12/21/2022 at Medicaid.Gov Survey of pharmacy drug pricing) | ||
TENOFOVIR DISOPROXIL FUMARATE 300 MG TABLET | Generic | $0.52 each |
viread (on 2/23/2022 at Medicaid.Gov Survey of pharmacy drug pricing) | ||
VIREAD 300 MG TABLET | Generic | $0.52 each |